Artax Biopharma
  • Resources
  • Partners
  • Media
  • Contact us
  • Our Approach
  • Our Patients
  • About Artax
  • Our Pipeline and Progress

Press Releases

  • Feature Jan 22, 2025

    Artax Biopharma achieves clinical validation of first-in-class, oral,  Nck modulator AX-158 for autoimmune disease in phase 2a study

    Cambridge, MA, January 22, 2025 – Artax Biopharma, Inc., a clinical-stage biotechnology company focused on transforming the…
    • Scientific Publication
    • Press Releases
    • Media
    • Press Releases
    Jan 4, 2024

    Artax Announces Executive Team Changes, Expansion as Company Heads into Pivotal2024 Year

    Former Board Chair Dr. Rob Armstrong Now Artax CEO as Joseph Lobacki Moves to Advisory…
    • Press Releases
    Nov 9, 2023

    Artax Granted Clinical Trial Authorization for AX-158 Phase 2a Psoriasis Study

    Artax Granted Clinical Trial Authorization for AX-158 Phase 2a Psoriasis Study Patient Enrollment Expected to…
    • Press Releases
    Jun 1, 2023

    Artax Biopharma Announces Positive Phase 1 Results for AX-158, Company’s First-in-Class Oral Immunomodulator Developed to Treat T Cell-Mediated Diseases 

    Phase 1 Findings Demonstrated that Investigational Agent AX-158 Was Well Tolerated at All Doses, with…
    • Press Releases
    Mar 7, 2023

    Artax Biopharma Appoints Andre Hoekema, Ph.D., to Company’s Board of Directors

    Company Welcomes Dr. Hoekema, a Biotech Veteran with a Track Record of Successful Industry Collaborations
    • Press Releases
    Nov 15, 2022

    Artax Biopharma Expands Company’s Scientific Advisory Board

    Company Welcomes James G. Krueger, M.D., Ph.D., and Ajay Nirula, M.D., Ph.D., Both Experts in…
    • Press Releases
    Jun 29, 2022

    Artax Biopharma Appoints D. Scott Batty, Jr., M.D. as Chief Medical Officer

    Dr. Batty Brings Significant Leadership Experience in Global Immunology and Clinical Development
    • Press Releases
    May 11, 2022

    Artax Biopharma Closes Financing to Advance Clinical Stage First-in- Class Oral Immunomodulator to Treat T Cell-Mediated Diseases

    Close of $26 Million Funds Immunomodulation Candidate AX-158 Development
    • Press Releases
    Dec 15, 2021

    Artax Biopharma Announces First-in-Human Dosing in Phase 1 Clinical Trial for AX-158, Company’s First-in-Class Oral Immunomodulator to Treat T Cell-Mediated Diseases

    The Phase 1 Trial, Expected to Conclude in 2022, Will Evaluate Safety, Exposure, and Pharmacokinetics…
    • Press Releases
    Jul 13, 2021

    Artax Biopharma Granted MHRA Clinical Trial Authorization for AX-158

    Authorization Represents Start of Clinical Program for Company’s Global Platform of T Cell-Mediated Diseases
Previous
1 2 3
Next

1 in 10 individuals is affected by autoimmune disease –
join our mission to treat them

Interested in learning more?

Ask us a question – the Artax team can help you

Get in touch
Clinical trials participation

Help us evaluate Nck modulation in clinical trials

About clinical trials
Partner with Artax

Explore Nck modulators for autoimmune conditions

About partnering with Artax

© Artax Biopharma. All Rights Reserved.

Terms of Use | Privacy Policy

Artax Biopharma
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}